In clinical applications, nanoparticle albumin-conjugated paclitaxel (nab-paclitaxel, nab-PTX) has been successfully used for targeted therapy of KRAS-mutant cancers (e.g., pancreatic cancer and breast cancer) [82]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.